TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05835934
Drug: [14C]HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous dose of 2 μg/0.212 μCi/kg \[14C\]HSK21542 in boluses within 2 minute after fasting for at least 10 hours.
Study: NCT00002036
Drug: Anti-HIV Immune Serum Globulin (Human)
Normalized name: immune globulin subcutaneous (human)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05043194
Drug: Ursodeoxycholic Acid 250 Mg Oral Capsule
Normalized name: Ursodeoxycholic acid 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: prevention
Study: NCT05261594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, oral intake
Study: NCT04562727
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: perioperative chemotherapy or postoperative chemotherapy
Study: NCT04493229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM
Study: NCT04625530
Drug: ferric carboxymaltose and tranexamic acid
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
Study: NCT06164951
Drug: Placebo Comparator 0.25 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
Study: NCT05580523
Drug: 75 mg acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
Study: NCT05580523
Drug: 150 mg acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg acetylsalicylic acid (C9H8O4, CAS number 50-78-2) daily, Oral
Study: NCT05580523
Drug: Placebo of acetylsalicylic acid and Metformin
Normalized name: codeine and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills with shape, color and smell same with acetylsalicylic acid and metformin, daily, oral
Study: NCT01028443
Drug: Artelose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05299411
Drug: iron (isomaltoside)
Normalized name: Iron isomaltoside 1000
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iron supplement through intravenous infusion
Study: NCT04765371
Drug: PREDNISOLONE
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take 60 mg per day of Prednisolone (40 mg morning and 20 md evening) between D1 to D10
Study: NCT04952779
Drug: Xultophy® (insulin degludec/liraglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study.
Study: NCT04882826
Drug: Viagra® film-coated tablet 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra® is manufactured by Fareva Amboise, France. Each tablet contains 100 mg of sildenafil.
Study: NCT05466240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 5 days
Study: NCT05966454
Drug: Multiple standard of care antibiotics for appendicitis, at physicians' discretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
Study: NCT05966454
Drug: Multiple standard of care antibiotics for appendicitis, at physicians' discretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
Study: NCT05326672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice daily for 8 weeks after enrolment.
Study: NCT00664690
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given preop and BID postop
Study: NCT05381194
Drug: BPaL(M) regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients diagnosed with MDR/RR-TB are initially assigned to the BPaLM regimen as a single-arm for treatment initiation. Afterward, if MDR/RR-TB is confirmed to be fluoroquinolone-resistant by molecular or phenotypic DST, the treatment is switched to the BPaL regimen (for 24 weeks). On the other hand, if MDR/RR-TB is confirmed to be fluoroquinolone-susceptible, treatment for MDR/RR-TB is maintained with the BPaLM regimen (for 26 weeks).~The dosage of each medication is as follows:~* Bedaquiline 400mg/day for the 2 weeks, 200mg/TIW afterward~* Pretomanid 200mg/day~* Linezolid 600mg/day for the 9weeks, 300mg/day afterward~* Moxifloxacin 400mg/day
Study: NCT05398055
Drug: Azithromycin + Doxycycline
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days
Study: NCT05398055
Drug: Placebo + Doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
Study: NCT00000834
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04646031
Drug: T89 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: T89 capsule, an medicinal product for oral use under active INDs in the US is a botanical drug containing 75mg active substance of the water extract of Danshen and Sanqi.
Study: NCT05241470
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in each eye twice a day
Study: NCT05611671
Drug: MORF-057
Approvals — FDA: no, EMA: no, PMDA: no
Description: MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Study: NCT05611671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (identical appearance to MORF-057) administered orally.
Study: NCT05020028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
Study: NCT06184633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm receives placebo in addition to combined lifestyle intervention
Study: NCT04802382
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the placebo treatment in addition to Standard of Care
Study: NCT04802382
Drug: CimetrA-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the study treatment, CimetrA-1 treatment in addition to Standard of Care
Study: NCT04802382
Drug: CimetrA-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive the study treatment, CimetrA-2 treatment in addition to Standard of Care
Study: NCT03380728
Drug: Ibogaine Hydrochloride
Normalized name: IBOGAINE HYDROCHLORIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
Study: NCT04921111
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: aluminium phosphate
Study: NCT06540443
Drug: MPB-2043 of 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
Study: NCT06540443
Drug: MPB-2043 of 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
Study: NCT06540443
Drug: MPB-2043 of 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
Study: NCT06540443
Drug: MPB-2043 of 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
Study: NCT00737542
Drug: NACL 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05121766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Soybean Oil Placebo capsules
Study: NCT05261386
Drug: CBT-008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat MGD
Study: NCT05359653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched sugar tablet
Study: NCT06038968
Drug: Methotrexate 25 MG/ML
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division.
Study: NCT05067621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pen contains excipients.
Study: NCT05919407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets will be identical apart from the active substance (pyridostigmine)
Study: NCT05919407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets will be identical apart from the active substance (amifampridine base)
Study: NCT05837338
Drug: BXP154
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXP154 will be self-administered topically following wound induction
Study: NCT05837338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be self-administered topically following wound induction
Study: NCT05647681
Drug: Douloff
Approvals — FDA: no, EMA: no, PMDA: no
Description: topic gel
Study: NCT05372718
Drug: Recombinant non-immunogenic staphylokinase (Fortelyzin®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilisate for preparation a solution
Study: NCT04980534
Drug: COVID-19 Standard Therapy
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Study: NCT06060236
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 800 Mg İv
Study: NCT06025318
Drug: PanCytoVir™
Approvals — FDA: no, EMA: no, PMDA: no
Description: PanCytoVir™ 100 mg/mL oral suspension
Study: NCT04824274
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
Study: NCT06165809
Drug: TQB3015 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3015 is a protein inhibitor
Study: NCT00000641
Drug: Amikacin sulfate
Normalized name: Amikacin Sulfate
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000641
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06372626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection
Study: NCT04733833
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT05990387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control condition
Study: NCT05638165
Drug: NCP112
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
Study: NCT04859296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized placebo
Study: NCT05763836
Drug: Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
Normalized name: ibuprofen 800 mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibuprofen infusion
Study: NCT06413693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of Placebo administered orally as tablets that look the same as PF-07293893
Study: NCT04779216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection monthly for 12 months
Study: NCT04779216
Drug: Alendronate 70Mg Tab
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70mg PO weekly starting at 12 months through 24 months.
Study: NCT04683315
Drug: mFOLFIRINOX Treatment Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
Study: NCT06263881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT06404112
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Study: NCT06404112
Drug: Melantonin Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Study: NCT06196736
Drug: 9MW2821
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle
Study: NCT06196736
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/m\^2 docetaxel by intravenous infusion or 175 mg/m\^2 paclitaxel by intravenous infusion on day 1 of every 21-day cycle.
Study: NCT05452525
Drug: CKD-379 I
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administration under fed condition
Study: NCT05452525
Drug: CKD-379 II
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administration under fed condition
Study: NCT05452525
Drug: D759+D745+D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablet coadministration under fed condition
Study: NCT05263739
Drug: ESG206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT05104866
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet. Oral route of administration. Active comparator
Study: NCT05959044
Drug: Folic Acid Tablet
Normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 5mg tablet two times daily for 8 weeks
Study: NCT04885257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT06168929
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640, 2.5mg\*4 - 10mg\*1
Study: NCT06168929
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640, 10mg\*1 - 2.5mg\*4
Study: NCT06220214
Drug: Omnipaque 350mgI/mL Solution for Injection
Normalized name: Omnipaque 350mgI/mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.
Study: NCT05506540
Drug: ENN0403 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT04820686
Drug: AB-729
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
Study: NCT05506540
Drug: ENN0403 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT04820686
Drug: SOC NrtI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Study: NCT05506540
Drug: ENN0403 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: ENN0403 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: ENN0403 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: ENN0403 20mg (Fed)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: ENN0403 6mg QD X 14 Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: ENN0403 12mg QD X 14 Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: ENN0403 20mg QD X 14 Days
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENN0403 capsules for oral use
Study: NCT05506540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for oral use
Study: NCT04773392
Drug: Once-daily envarsus XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 48 hours of transplantation, Envarsus XR (0.13mg/kg/day) will be administered once a day.
Study: NCT04773392
Drug: Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) (up to 1000mg) or Mycophenolic acid (MPA) (up to 720mg) will be administered twice a day.
Study: NCT06355024
Drug: Inosine
Normalized name: Inosine
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral inosine 200mg tid
Study: NCT04773392
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (1-3 mg/kg) will be administered once a day.
Study: NCT05837455
Drug: Combination anthracycline and/or taxane based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT05237752
Drug: LG00034053
Approvals — FDA: no, EMA: no, PMDA: no
Description: a pan-caspase inhibitor, as a therapeutic agent of osteoarthritis
Study: NCT05786404
Drug: PRIM-DJ2727 - CAPSULES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
Study: NCT05272683
Drug: GLPG3667
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 1 and day 8, participants will receive a single dose
Study: NCT00002088
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05602493
Drug: Soludronate®
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the first visit, the randomized process will take place. Tooth extraction procedure will be performed.
Study: NCT05602493
Drug: sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile saline
Study: NCT04588922
Drug: SLS009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT06509906
Drug: Fluorouracil (5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil will be administered intravenously as per standard of care.
Study: NCT04965987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06486805
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) is a small molecule containing a thiol (sulfhydryl-containing) group, which has antioxidant properties and is freely filterable, thus making it readily accessible to the intracellular compartment
Study: NCT05545891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A drug that contains no medicine
Study: NCT04850222
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
Study: NCT04850222
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
Study: NCT05901285
Drug: VAX014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
Study: NCT05413655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage form of Placebo is the capsule for oral use
Study: NCT06175338
Drug: MabThera®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MabThera® 1000 mg in 150 ml 0,9 % NaCl (total volume of infusion 250 ml)
Study: NCT04003285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
Study: NCT06191848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo subcutaneously